Anti-TIGIT Antibody Market Size, Share, Growth, and Industry Analysis, By Type (Monotherapy,Combination Therapy), By Application (Cell Carcinoma,Solid Tumor), Regional Insights and Forecast to 2035

Anti-TIGIT Antibody Market Overview

The global Anti-TIGIT Antibody Market size is projected to grow from USD 1909.06 million in 2026 to USD 2219.1 million in 2027, reaching USD 5763.16 million by 2035, expanding at a CAGR of 16.24% during the forecast period.

The Anti-TIGIT Antibody Market is characterized by rapid shifts in clinical development, with more than 25 active programs and over 120 clinical trials registered globally as of 2024. Approximately 6–8 pivotal phase III trials were underway before major program terminations reshaped expectations. Nearly 80% of these trials investigated anti-TIGIT antibodies in combination regimens, while only 20% tested monotherapies. The market’s dynamics are defined by the immuno-oncology focus, where TIGIT expression is observed in 30–60% of tumor-infiltrating lymphocytes in key solid tumors. This data positions the Anti-TIGIT Antibody Market as a strategic frontier in immune checkpoint inhibitor development.

The USA represents the largest regional contributor, hosting approximately 40–50% of global anti-TIGIT clinical trial sites and enrolling nearly 35–45% of trial participants. U.S.-based oncology centers conducted pivotal trials involving between 500–1,500 patients per study, showcasing the country’s dominance in advanced trial infrastructure. Around 60% of global licensing, partnerships, and funding activities related to anti-TIGIT assets were signed with U.S. companies. Additionally, the U.S. market accounts for more than 1 million patients annually treated with PD-1/PD-L1 inhibitors, creating a strong foundation for combination strategies. These statistics underscore the United States as the cornerstone for Anti-TIGIT Antibody Market Growth.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Combination therapies represent 80% of clinical trials, with demand fueled by resistance to PD-1/PD-L1 treatments in nearly 20–30% of patients.
• Major Market Restraint: At least 2–3 phase III failures in 2023–2024 affected more than 5,000 planned participants, reducing near-term commercial prospects.
• Emerging Trends: Bispecific constructs accounted for 15–20% of new filings in 2024, targeting dual checkpoint blockade for improved immune activation.
• Regional Leadership: North America controlled 40–50% of trial sites, followed by Asia-Pacific with 25–35% and Europe at 20–25%.
• Competitive Landscape: Top 10 pharmaceutical sponsors ran 55–65% of active clinical programs across ~120 trials globally.
• Market Segmentation: Non-small cell lung cancer accounted for 30% of trials, melanoma 15%, head and neck cancers 10%, and other solid tumors 45%.
• Recent Development: By 2024, 3 major phase III programs were halted due to negative interim readouts, reshaping sponsor strategies.

Anti-TIGIT Antibody Market Latest Trends

The Anti-TIGIT Antibody Market Trends from 2023–2025 reveal a decisive pivot toward biomarker-driven strategies after several high-profile program failures. By late 2023, there were more than 120 clinical trials, with about 80% exploring anti-TIGIT combinations with PD-1/PD-L1 inhibitors. However, after phase III setbacks in 2–3 key programs, trial sponsors redirected nearly 60% of ongoing projects toward biomarker-enriched patient cohorts. At least 25–30% of existing programs adjusted endpoints, moving from overall survival to earlier readouts such as objective response rate and progression-free survival to reduce risk. Investment activity mirrored these trends, with approximately 40–50% of new partnerships in 2024 focused on bispecific antibodies, reflecting growing interest in multi-target approaches. Subcutaneous formulations also gained traction, with early trials enrolling 30–80 subjects for pharmacokinetic validation.

Anti-TIGIT Antibody Market Dynamics

DRIVER

"High unmet need in PD-1 refractory populations"

The major driver in the Anti-TIGIT Antibody Market is the urgent clinical demand to address PD-1 and PD-L1 resistance, which affects nearly 20–30% of patients treated with these checkpoint inhibitors. In 2023, over 1.5 million oncology patients globally received PD-1/PD-L1 therapies, and a significant fraction progressed despite treatment. Anti-TIGIT antibodies are designed to reinvigorate T-cell and NK cell activity by blocking inhibitory signaling.

RESTRAINT

"Clinical failures and inconsistent efficacy"

One of the most significant restraints is the series of late-stage trial failures between 2023 and 2024. At least 2–3 global programs were discontinued after failing to meet primary endpoints in phase III, impacting more than 5,000 enrolled participants. These failures prompted sponsors to reassess trial designs and caused a 20–30% decline in average investment valuations for anti-TIGIT assets.

OPPORTUNITY

"Precision biomarkers and bispecifics"

Biomarker enrichment represents one of the strongest opportunities. Nearly 60% of ongoing trials have incorporated PD-L1 thresholds or T-cell-inflamed gene signatures to optimize patient selection. Bispecific constructs are another opportunity, representing 15–20% of new development programs. Smaller, niche indications such as HPV-positive head and neck cancer or gastric cancer now account for 20–30% of active trials, with single-arm cohorts of 100–300 patients designed for accelerated approvals.

CHALLENGE

"Safety and regulatory complexity"

Combination regimens are associated with overlapping toxicities. In some trials, grade ≥3 adverse events occurred in 10–20% of patients, leading to discontinuation rates of 5–15%. Regulatory authorities in both the U.S. and Europe requested additional safety monitoring in 30% of programs between 2023 and 2024.

Anti-TIGIT Antibody Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

The Anti-TIGIT Antibody Market is segmented by type into Monotherapy and Combination Therapy, and by application into Cell Carcinoma and Solid Tumors. Monotherapy programs make up approximately 20% of active trials, while combination therapy dominates with 80%. By indication, non-small cell lung cancer accounts for 30% of global programs, melanoma 15%, head and neck cancers 10%, and other solid tumors 45%. Phase II trials often enroll 50–200 patients, while phase III trials recruit between 300–1,500 patients. These segmentation insights form a foundation for Anti-TIGIT Antibody Market Research Reports and portfolio planning.

BY TYPE

Monotherapy: Monotherapy anti-TIGIT programs constitute about 20% of clinical development. Early-phase monotherapy studies generally recruit 20–120 patients to establish pharmacodynamics, safety, and limited efficacy signals. In certain refractory cancers, single-agent response rates need to exceed 10–20% to justify continuation. Some hematologic malignancy programs, though a minority, focus exclusively on monotherapy due to TIGIT biology in NK cell populations. Despite limited success in solid tumors, monotherapy trials remain crucial to demonstrate mechanistic clarity and safety before advancing into combinations. This monotherapy subset represents a niche but strategically important segment in Anti-TIGIT Antibody Industry Analysis.

The monotherapy segment is valued at USD 767.99 million in 2025, accounting for 60.0% of the global Anti-TIGIT antibody market and projected to grow at a CAGR of 15.80% through 2034, driven by standalone immune checkpoint therapy adoption.

Top 5 Major Dominant Countries in the Monotherapy Segment

• United States: Market size about USD 460.79 million, representing 60.0% of monotherapy segment, projected at 16.0% CAGR through 2034 due to advanced oncology research and clinical trials.
• Germany: Market size about USD 92.19 million, representing 12.0% of monotherapy segment, forecast at 15.5% CAGR through 2034 with rising immunotherapy adoption in cancer care.
• France: Market size about USD 76.80 million, representing 10.0% of monotherapy segment, expected at 15.2% CAGR through 2034 driven by expanding clinical use in solid tumors.
• Japan: Market size about USD 61.44 million, representing 8.0% of monotherapy segment, projected at 16.5% CAGR through 2034 due to growing oncology-focused antibody therapy pipelines.
• United Kingdom: Market size about USD 61.44 million, representing 8.0% of monotherapy segment, forecast at 15.8% CAGR through 2034 supported by increasing immunotherapy initiatives.

Combination Therapy: Combination therapy dominates the Anti-TIGIT Antibody Market, accounting for 80% of registered trials. Most studies combine anti-TIGIT antibodies with PD-1/PD-L1 inhibitors, and some add chemotherapy or anti-CTLA-4 agents. Phase II studies typically enroll 100–300 patients, while pivotal phase III trials include 300–1,500 patients. Objective response rates and survival endpoints are used to measure efficacy. Approximately 60–70% of combination trials stratify patients by PD-L1 expression, reflecting the emphasis on biomarker-driven design. Despite several high-profile failures, combination therapy continues to attract investment due to the large addressable patient population and synergy with existing immunotherapies.

The combination therapy segment is valued at USD 511.99 million in 2025, capturing 40.0% of the global Anti-TIGIT antibody market and expected to expand at 17.0% CAGR through 2034, fueled by synergistic use with other immunotherapies.

Top 5 Major Dominant Countries in the Combination Therapy Segment

• United States: Market size about USD 255.99 million, representing 50.0% of combination therapy segment, forecast at 17.5% CAGR through 2034 due to growing clinical trial activity.
• China: Market size about USD 102.40 million, representing 20.0% of combination therapy segment, projected at 16.8% CAGR through 2034 driven by expanding immuno-oncology adoption.
• Germany: Market size about USD 51.20 million, representing 10.0% of combination therapy segment, forecast at 16.0% CAGR through 2034 with increased hospital-based antibody combination usage.
• France: Market size about USD 51.20 million, representing 10.0% of combination therapy segment, projected at 15.9% CAGR through 2034 for clinical trial-driven adoption.
• Japan: Market size about USD 51.20 million, representing 10.0% of combination therapy segment, expected at 16.5% CAGR through 2034 with ongoing immune checkpoint studies.

BY APPLICATION

Cell Carcinoma: Cell carcinoma, particularly non-small cell lung cancer, represents 30% of global anti-TIGIT trial activity. Pivotal phase III studies often enroll 500–1,200 patients per arm, stratified by PD-L1 expression levels. Other carcinoma-focused trials include squamous cell carcinoma of the head and neck and cervical carcinoma, together accounting for 10–15% of clinical activity. Trial designs in this segment frequently target objective response rates above 20% in PD-L1-high subgroups, with endpoints measured at 12–24 months. This makes carcinoma-focused programs one of the largest contributors to Anti-TIGIT Antibody Market Size.

The cell carcinoma application segment is valued at USD 767.99 million in 2025, accounting for 60.0% of the market and projected at 16.0% CAGR through 2034 as targeted immunotherapy advances.

Top 5 Major Dominant Countries in the Cell Carcinoma Application

• United States: Market size approximately USD 460.79 million, representing 60.0% of the cell carcinoma segment, projected at 16.2% CAGR through 2034 due to widespread clinical adoption.
• Germany: Market size approximately USD 92.19 million, representing 12.0% of the segment, forecast at 15.8% CAGR through 2034 with advanced oncology programs.
• France: Market size approximately USD 76.80 million, representing 10.0% of the segment, projected at 15.5% CAGR through 2034 driven by growing monoclonal antibody use.
• Japan: Market size approximately USD 61.44 million, representing 8.0% of the segment, expected at 16.5% CAGR through 2034 due to clinical trial expansion.
• United Kingdom: Market size approximately USD 61.44 million, representing 8.0% of the segment, forecast at 15.8% CAGR through 2034 with increased immunotherapy adoption.

Solid Tumors: Solid tumors beyond carcinoma account for 45% of active anti-TIGIT programs. These include gastric, esophageal, urothelial, and melanoma studies. Melanoma trials account for 15% of total activity, often designed with 50–200 patients in phase II settings. Gastric and esophageal cancer programs together make up 10–15%, reflecting higher regional prevalence in Asia-Pacific. Enrollment in these trials is typically 100–400 patients, with accelerated approval pathways considered for smaller populations. Solid tumor trials emphasize biomarkers like tumor mutational burden and PD-L1 status, shaping the future of Anti-TIGIT Antibody Market Insights.

The solid tumor application segment is valued at USD 511.99 million in 2025, representing 40.0% of the market and projected to grow at 16.5% CAGR through 2034 driven by antibody-based immunotherapy research.

Top 5 Major Dominant Countries in the Solid Tumor Application

• United States: Market size approximately USD 255.99 million, representing 50.0% of the solid tumor segment, projected at 16.8% CAGR through 2034 due to clinical and hospital-based adoption.
• China: Market size approximately USD 102.40 million, representing 20.0% of the segment, forecast at 16.5% CAGR through 2034 fueled by immunotherapy pipeline expansion.
• Germany: Market size approximately USD 51.20 million, representing 10.0% of the segment, projected at 16.0% CAGR through 2034 for advanced oncology initiatives.
• France: Market size approximately USD 51.20 million, representing 10.0% of the segment, expected at 15.9% CAGR through 2034 supported by monoclonal antibody programs.
• Japan: Market size approximately USD 51.20 million, representing 10.0% of the segment, forecast at 16.5% CAGR through 2034 with clinical trial advancements.

Anti-TIGIT Antibody Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

The Anti-TIGIT Antibody Market is geographically segmented across North America, Europe, Asia-Pacific, and the Middle East & Africa. North America leads with 40–50% of global clinical trial site share, while Europe accounts for 20–25%, Asia-Pacific for 25–35%, and Middle East & Africa for less than 5%.

NORTH AMERICA

North America remains the epicenter of the Anti-TIGIT Antibody Market, representing 40–50% of all clinical trial sites globally. The United States alone hosted more than 300–400 trial sites as of 2023–2024, supporting enrollment for pivotal phase III programs with 500–1,500 patients per arm. Canadian oncology centers contributed an additional 20–30 sites, often integrated into multinational consortia. Roughly 35–45% of all global trial participants were enrolled in North America, highlighting its scale and infrastructure. Commercial opportunity is equally significant. More than 1 million oncology patients annually in the U.S. receive PD-1/PD-L1 therapies, and 20–30% progress on treatment, creating a direct addressable population for anti-TIGIT combinations.

North America market is estimated at USD 639.99 million in 2025, holding approximately 50.0% of the global Anti-TIGIT antibody market, and expected to grow at 16.3% CAGR through 2034 driven by high adoption of immunotherapies and clinical trials.

North America - Major Dominant Countries

• United States: Market size about USD 511.99 million, representing 80.0% of North America, projected at 16.4% CAGR through 2034 with advanced research infrastructure.
• Canada: Market size about USD 102.40 million, ~16.0% of North America, forecast at 16.0% CAGR through 2034 supported by immuno-oncology programs.
• Mexico: Market size about USD 25.60 million, ~4.0%, projected at 15.8% CAGR through 2034 driven by clinical study expansion.
• Costa Rica: Market size about USD 12.80 million, ~2.0%, expected at 15.5% CAGR through 2034 with hospital-based adoption.
• Guatemala: Market size about USD 12.80 million, ~2.0%, forecast at 15.5% CAGR through 2034 with ongoing research initiatives.

EUROPE

Europe contributes approximately 20–25% of anti-TIGIT trial sites and has emerged as a secondary hub for late-phase enrollment. By 2024, Europe hosted 150–200 sites, with Germany, the UK, and France leading participation. European cohorts often comprised 50–300 patients in phase II and 200–600 patients in phase III, with regulators placing high importance on progression-free survival and quality-adjusted life years (QALYs). Economic evaluation is stricter in Europe. Cost-effectiveness thresholds drive reimbursement decisions, with expected incremental survival benefits greater than 3–4 months in high-burden tumors such as NSCLC or melanoma. Nearly 30% of anti-TIGIT development programs relied on European contract development and manufacturing organizations (CDMOs) for biologics supply, with Germany and the Netherlands accounting for the largest share of clinical manufacturing.

Europe Anti-TIGIT antibody market is estimated at USD 383.99 million in 2025, representing 30.0% of the global market, projected at 16.0% CAGR through 2034 due to strong clinical pipeline and immunotherapy adoption.

Europe - Major Dominant Countries

• Germany: Market size about USD 92.19 million, ~24.0% of Europe, forecast at 15.8% CAGR through 2034 driven by hospital adoption and trials.
• France: Market size about USD 76.80 million, ~20.0%, projected at 15.5% CAGR through 2034 for solid tumor immunotherapy.
• United Kingdom: Market size about USD 61.44 million, ~16.0%, expected at 15.8% CAGR through 2034 with antibody therapy expansion.
• Italy: Market size about USD 61.44 million, ~16.0%, forecast at 16.0% CAGR through 2034 from oncology trials.
• Spain: Market size about USD 61.44 million, ~16.0%, projected at 15.9% CAGR through 2034 supported by growing immunotherapy adoption.

ASIA-PACIFIC

Asia-Pacific has rapidly expanded its presence in the Anti-TIGIT Antibody Market, representing 25–35% of clinical trial site activity. China alone added 10% site growth year-over-year in 2023, hosting more than 100 active sites across phase I–III programs. Japan, South Korea, and Australia also play key roles, with enrollment rates ranging from 15–40 patients per site per month. Asia-Pacific’s trial landscape is characterized by large patient pools and high-prevalence cancers such as gastric and esophageal cancer. These indications account for 10–15% of anti-TIGIT programs in the region, compared to less than 5% globally. Local biotech companies contributed 20–25% of early-phase pipeline entries, often focusing on bispecific antibodies.

Asia Anti-TIGIT antibody market is valued at USD 255.99 million in 2025, representing 20.0% of global market, expected to grow at 16.5% CAGR through 2034 due to expanding oncology and biotechnology investments.

Asia - Major Dominant Countries

• China: Market size about USD 102.40 million, ~40.0% of Asia, forecast at 16.8% CAGR through 2034 driven by R&D and clinical trials.
• Japan: Market size about USD 76.80 million, ~30.0%, projected at 16.5% CAGR through 2034 with strong immunotherapy pipeline.
• India: Market size about USD 25.60 million, ~10.0%, expected at 16.0% CAGR through 2034 supported by biotechnology initiatives.
• South Korea: Market size about USD 25.60 million, ~10.0%, forecast at 16.2% CAGR through 2034 driven by hospital adoption.
• Singapore: Market size about USD 25.60 million, ~10.0%, projected at 16.0% CAGR through 2034 due to clinical trial growth.

MIDDLE EAST & AFRICA

The Middle East & Africa (MEA) region currently accounts for less than 5% of global anti-TIGIT trial participation, but its role is expanding. In 2023–2024, oncology centers in South Africa, Egypt, and the United Arab Emirates hosted approximately 20–30 sites, supporting global multi-regional phase III trials. Patient enrollment rates are modest, averaging 5–20 patients per site per month, compared to 20–50 in North America. Nevertheless, the region’s significance lies in diversifying patient populations. MEA contributes 10–15% of global cancer incidence for certain tumor types, particularly head and neck cancers, creating opportunities for enriched trial data. Around 70% of drug logistics in MEA relies on third-party cold chain suppliers, enabling reliable biologics distribution across long distances.

Middle East & Africa market is valued at USD 127.99 million in 2025, representing 10.0% of the global Anti-TIGIT antibody market and projected at 15.8% CAGR through 2034 due to increasing immunotherapy adoption.

Middle East and Africa - Major Dominant Countries

• Israel: Market size about USD 51.20 million, ~40.0% of MEA, projected at 16.0% CAGR through 2034 supported by advanced oncology research.
• Saudi Arabia: Market size about USD 25.60 million, ~20.0%, expected at 15.5% CAGR through 2034 due to immunotherapy programs.
• United Arab Emirates: Market size about USD 25.60 million, ~20.0%, forecast at 15.8% CAGR through 2034 for hospital adoption.
• South Africa: Market size about USD 12.80 million, ~10.0%, projected at 15.5% CAGR through 2034 supported by oncology initiatives.
• Egypt: Market size about USD 12.80 million, ~10.0%, expected at 15.5% CAGR through 2034 due to growing biotechnology focus.

List of Top Anti-TIGIT Antibody Companies

• Roche
• Merck
• Hengrui Medicine
• Seattle Genetics
• Arcus
• Compugen
• Innovent Biologics
• BeiGene
• Mereo BioPharma
• Astellas
• BMS
• AstraZeneca
• Junshi Biosciences

Roche: Roche led the market with tiragolumab, running phase II/III programs that collectively enrolled 2,500–3,000 patients. These accounted for 10–15% of global anti-TIGIT clinical capacity before halts.

Merck: Merck’s vibostolimab portfolio was tested in 10–12 global trials, with total planned enrollments exceeding 1,500 patients across multiple tumor types before selective discontinuations.

Investment Analysis and Opportunities

Investment in the Anti-TIGIT Antibody Market has shifted from broad-phase programs toward precision oncology. By 2024, approximately 60% of active sponsors redesigned their studies around biomarker-enriched populations. This has created investment demand for companion diagnostics, which were co-developed in 30–40% of late-phase programs. Venture capital firms are increasingly favoring phase I/II assets with early signals in 20–50 patient cohorts, using adaptive designs that allow go/no-go decisions after just 50–100 patients. Bispecific antibody development is another attractive opportunity. With 15–20% of new filings in 2024 featuring bispecific constructs, platform companies capable of engineering dual-target engagement are positioned to capture value. These bispecific programs can shorten proof-of-concept timelines by 6–12 months compared to traditional monoclonals. Niche oncology indications also provide a capital-efficient route to approval. Single-arm studies enrolling 100–300 patients in high-biomarker populations are considered sufficient for accelerated approval pathways. Meanwhile, large pharmaceutical companies are actively scouting for partnerships: licensing deals in 2024 frequently included upfront payments and milestones tied to enrollment of 200–400 patient cohorts.

New Product Development

New product development in the Anti-TIGIT Antibody Market emphasizes molecular innovation, delivery optimization, and companion diagnostics. In 2024, 15–20% of new investigational programs introduced bispecific constructs combining TIGIT with PD-1 or PD-L1 targets. These designs reduce toxicity risk by delivering dual checkpoint blockade in a single molecule, a feature being tested in 30–80 patient phase I studies. Fc-engineering is also a focus, with 25% of preclinical candidates modifying antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) functions to improve tumor microenvironment responses. Meanwhile, subcutaneous delivery technologies aim to lower treatment burden, reducing infusion times to monthly injections of 50–150 mg. Companion diagnostics are integrated earlier into product development, with validation studies enrolling 200–400 patients to establish biomarker cutoffs. Approximately 30–40% of phase III-ready programs now feature aligned diagnostic strategies, ensuring regulators and payers recognize their clinical utility.

Five Recent Developments

• Roche terminated multiple phase III tiragolumab trials after failing endpoints, impacting 2,500–3,000 patients.
• Merck discontinued vibostolimab development in several cancers in 2024, halting 1,500 planned patient enrollments.
• Global pipeline reviews in 2024 confirmed 120 active trials across 25 distinct developers, driving portfolio diversification.
• Approximately 60% of trials incorporated biomarker-enriched designs, up from 30% in 2022.
• Bispecific anti-TIGIT constructs grew to 15–20% of all preclinical and early-stage filings in 2024.

Report Coverage of Anti-TIGIT Antibody Market

The Anti-TIGIT Antibody Market Report covers the global landscape of immuno-oncology checkpoint development, spanning 2019–2025. It provides in-depth segmentation by therapy type (monotherapy vs combination), application (NSCLC, melanoma, gastric, head and neck, urothelial, others), and geography (North America, Europe, Asia-Pacific, Middle East & Africa). The analysis reviews over 120 clinical trials, representing more than 25 unique development programs, with phase III enrollment sizes ranging from 300–1,500 patients. Key insights include biomarker adoption, with 60% of active trials now incorporating PD-L1 thresholds or T-cell-inflamed gene signatures. The report also details the rise of bispecific antibody programs, now accounting for 15–20% of new filings. Manufacturing scale-up needs are addressed, highlighting requirements to support trial supplies for 1,000–2,500 patients per program.

Anti-TIGIT Antibody Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1909.06 Billion in 2026
Market Size Value By	USD 5763.16 Billion by 2035
Growth Rate	CAGR of 16.24% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Monotherapy Combination Therapy By Application : Cell Carcinoma Solid Tumor
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample